Environmental Analysis Health and Toxicology

The Korean Society of Environmental Health and Toxicology (환경독성보건학회)
권호 표지

Effects of Nalbuphine on the Primary Humoral Immune Response in Mice

Nalbuphine이 마우스의 일차 체액성 면역반응에 미치는 영향

  • Yun, Hee-Eun (College of Pharmacy, Sookmyung Women's University) ;
  • Pyo, Myoung-Yun (College of Pharmacy, Sookmyung Women's University)
  • 윤희은 (숙명여자대학교 약학대학) ;
  • 표명윤 (숙명여자대학교 약학대학)
  • Published : 2005.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

In order to investigate the of effects of nalbuphine on immune system in mice, we examined the various immunological parameters. After single oral administration of nalbuphine (130, 260, 390 mg/kg, i.p.) to female ICR mite, the weights of bodies and organs (thymus, spleen, liver, kidney), and hematological parameters were examined on day 2, 4, 6, and 8. The increased rate of body weight, relative weight of organ, and hematological parameters in nalbuphine -treated groups, were not significantly changed when compared with control group. However, number of WBC was decreased by the treatment of nalbuphine. To assess the effects of nalbuphine on humoral immune responses, splenic IgM plaque forming cell (PFC) and serum IgM were assayed. When nalbuphine wat administered after immunization with SRBC, but not before immunization, splenic IgM PFC and ,serum IgM level against SRBC were significantly lowered in a dole -dependent manner. These results indicate that the suppressive effects of nalbuphine on primary humoral immune response may be dependent on the timing of its administration relative to the initial antigenic sensitization.

Keywords

References

  1. Cada DJ, Covington T, Hebel SK, Hussar DA, Lasagna L and Olin BR. Drug facts and comparisons, 1999 Edition, Facts and Comparisons 1999, pp 1433-1434
  2. Chung HS. Pharmacokinetics of nalbuphine in overdosage as a psychotropic agent, Annual Report of N.I.S.I., 2002; 34: 149-154
  3. Cunnigham A and Szenberg A. Futher improvements in plaque technique for detecting single antibody-forming cells, Immunol 1968; 14: 599-600
  4. Kaminski NE. Mechanism of immune modulation by cannabinoids, in Dean JH, Luster MI, Munson AE, Kimber I (eds): Immunotoxicology and Immunopharmacology, 2d ed. New York: Raven Press, 1994, pp. 349-362
  5. LeVier DG, McCay JA and Stern ML. Immunotoxicological profile of morphine sulfate in B6C3F1 mice, Fundam Appl Toxicol 1994; 22: 525-542 https://doi.org/10.1006/faat.1994.1060
  6. Litchfield JT and Wilcoxon F. A simplified Method of Evaluating Dose-effect Experiments, J Pharmacol Exp Ther 1943; 96: 99-113
  7. Lo MW, Schary WL and Whitney CC. The disposition and bioavailability of intravenous and oral nalbuphine in healthy volunteers, J Clin Pharmaco 1983; 27: 866-873
  8. Loren DK. Decreased antibody formation in mice exposed to lead, Nature 1974; 250: 148-250 https://doi.org/10.1038/250148a0
  9. Matveyeva M, Hartman CB and Harrison MT. Delta(9)-tetrahydrocannabinol selectively increases aspartyl cathepsin D proteolytic activity and impairs lysozomal processing in macrophages, Int J Immunopharmacol 2000; 22(5): 373-381 https://doi.org/10.1016/S0192-0561(99)00092-2
  10. McBride AJ. Three cases of nalbuphine hydrochloride dependence associated with anabolic steroid use, Br J Sports Med 1996; 30: 69-70 https://doi.org/10.1136/bjsm.30.1.69
  11. Mischell BB and Shiigi SM. Selected methods in cellular immunology, WH Freman and Company, San Francisco, U.S.A .. 1980, pp. 16-17
  12. Reynolds EF. In Martindale The Extra Phamacopoeia, 13th ed., Pharmaceutical Press, London, England, 1993, pp. 1090
  13. Smialowicz RJ and Holsapple MP. Experimental Immuno-toxicology Boca Raton, FL, CRC Press, 1996, pp. 13-15
  14. Stambaugh JE. Evaluation of nalbuphine; Efficacy and Safety in the Management of Chronic Pain Associated With Advanced Malignancy, Current Therapeutic Research. 1982; 31(3): 393-401
  15. Yoo YC, Chung HS and Kim IS. Determination of Nalbuphine in Drug Abuser' Urine, J of Analytical Toxicology 1995; 19: 120-123 https://doi.org/10.1093/jat/19.2.120